Adverum Biotechnologies, Inc. (ADVM) earnings
ADVM earnings moved a median of +2.52% by the close. Quarterly and annual ADVM reports and results, each read against the price at its own news timestamp. Back to the ADVM overview →
16 measured ADVM earnings events.
Where these ADVM earnings landedvs 13 measured ADVM earnings reactions
| Middle 50% of ADVM earnings reactions | -1.59% to +3.21% |
|---|---|
| Median reaction (to close) | +2.52% |
| Measured reactions | 13 |
Point-in-time · zero look-ahead
Half of the 13 ADVM earnings events with a measured close landed between -1.59% and +3.21%; 69% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Adverum Biotechnologies, For: Sep 30 | SEC filing · Form 10-Q | +0.12% | — | |
| Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights | Press release | +1.77% | — | |
| Form 10-Q Adverum Biotechnologies, For: Jun 30 | SEC filing · Form 10-Q | +1.77% | — | |
| Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights | Press release | -2.00% | +2.50% | |
| Form 10-Q Adverum Biotechnologies, For: Mar 31 | SEC filing · Form 10-Q | -2.00% | +2.50% | |
| Form 10-K Adverum Biotechnologies, For: Dec 31 | SEC filing · Form 10-K | +1.77% | -4.72% | |
| Form NT 10-K Adverum Biotechnologies, For: Dec 31 | SEC filing · Form NT | +1.01% | -10.09% | |
| Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones | Press release | -0.92% | +2.52% | |
| Form 10-Q Adverum Biotechnologies, For: Sep 30 | SEC filing · Form 10-Q | -0.92% | +2.52% | |
| Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights | Press release | +4.88% | +3.21% | |
| Form 10-Q Adverum Biotechnologies, For: Jun 30 | SEC filing · Form 10-Q | +4.88% | +3.21% | |
| Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights | Press release | +4.23% | -1.59% | |
| Form 10-Q Adverum Biotechnologies, For: Mar 31 | SEC filing · Form 10-Q | +4.23% | -1.59% | |
| Form 10-K Adverum Biotechnologies, For: Dec 31 | SEC filing · Form 10-K | +0.33% | +10.00% | |
| Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights | Press release | +1.24% | +7.41% | |
| Form 10-Q Adverum Biotechnologies, For: Sep 30 | SEC filing · Form 10-Q | +1.24% | +7.41% |
Keep exploring
More ADVM: analyst actions → · SEC filings → · ADVM overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MENLO THERAPEUTICS INC COMMON (MNLO) | 308 | 0.00% | 49% |
| Syros Pharmaceuticals, Inc. (SYRS) | 307 | +0.51% | 55% |
| Establishment Labs Holdings Inc. - Common Shares (ESTA) | 306 | +0.13% | 52% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 306 | +0.04% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.